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Abstract
Purpose: This study aims to determine whether there is consensus regarding
staging and management of cutaneous squamous cell carcinoma (CSCC) across
the various specialties that manage this disease.
Materials and Methods: A survey regarding CSCC high-risk features, staging,
and management was created and emailed to cutaneous oncology experts including dermatology, head and neck surgery/surgical oncology, radiation oncology,
and medical oncology.
Results: One hundred fifty-six (46%) of 357 invited physicians completed the
survey. Depth of invasion (92%), perineural invasion (99%), histologic differentiation (85%), and patient immunosuppression (90%) achieved consensus (>80%) as
high-risk features of CSCC. Dermatologists were more likely to also choose clinical tumor diameter (79% vs. 54%) and histology (99% vs. 66%) as a high-risk feature. Dermatologists were also more likely to utilize the Brigham and Women's
Hospital (BWH) staging system alone or in conjunction with American Joint
Committee on Cancer (AJCC) (71%), whereas other cancer specialists (OCS) tend
to use only AJCC (71%). Respondents considered AJCC T3 and higher (90%) and
BWH T2b and higher (100%) to be high risk and when they consider radiologic
imaging, sentinel lymph node biopsy, post-operative radiation therapy, and increased follow-up. Notably, a large number of respondents do not use staging
systems or tumor stage to determine treatment options beyond surgery in high-
risk CSCC.
Conclusion: This survey study highlights areas of consensus and differences
regarding the definition of high-risk features of CSCC, staging approaches, and
management patterns between dermatologists and OCS. High-risk CSCC is defined as, but not limited to, BWH T2b and higher and AJCC T3 and higher, and
these thresholds can be used to identify cases for which treatment beyond surgery
may be considered. Dermatologists are more likely to utilize BWH staging, likely
because BWH validation studies showing advantages over AJCC were published
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in dermatology journals and discussed at dermatology meetings. Additional data
are necessary to develop a comprehensive risk-based management approach for
CSCC.
KEYWORDS

American Joint Committee on Cancer Staging System, Brigham and Women Staging System,
depth of tumor, high-risk cutaneous squamous cell carcinoma, high-risk tumor features,
histologic differentiation, immunosuppression, perineural invasion, skin cancer, staging
criteria, tumor diameter, tumor location
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I N T RO DU CT ION

Cutaneous squamous cell carcinoma (CSCC) is a rising
epidemic, and while most tumors having an excellent
prognosis, 4%–6% of tumors metastasize and 1.5%–2%
lead to death.1–4 Over the past several years, multiple
CSCC staging systems and guidelines have been developed that vary in tumor assessment, including the AJCC
8th Edition (AJCC), Brigham and Women's Hospital tumor
staging system (BWH), University Hospital Tubingen
(UHT) system, and National Comprehensive Cancer
Network (NCCN) guidelines.5 With no universal accepted
definition of high-risk CSCC (HRCSCC), clear management guidelines are lacking. Point estimates of risk for
recurrence and metastasis by tumor stage have varied between studies.6–8 Subsequently, studies have found notable differences regarding the perioperative management
of HRCSCC among Mohs surgeons, radiation oncologists,
and head and neck surgeons.9,10 Due to a paucity of data
regarding the utility of nodal staging and adjuvant therapy, HRCSCC treatment is inconsistent and based on anecdotal experience.
This study aims to assess how physicians across the
fields of dermatology, head and neck surgery/surgical
oncology, radiation oncology, and medical oncology (latter three groups categorized as Other Cancer Specialists
[OCS]) define HRCSCC and approach high risk, advanced,
and/or metastatic CSCC. We hypothesized that there is
variability between dermatologists and OCS with regard
to HRCSCC definition, staging utilization, and management. Areas of consensus and areas needing clarification
with future studies are identified.

2
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M ET H ODS

A 25-question “Cutaneous SCC Staging Survey” (Figure
S1) was developed by four of the authors (VAP, AJP,
CDS, and STA) encompassing the management of

HRCSCC. A list of dermatologists from the International
Immunosuppression and Transplant Skin Cancer
Collaborative and the American College of Mohs Surgery
MohsAIQ registry, considered experts in cutaneous oncology, was created.11 These individuals were contacted
by email for OCS colleague referrals who frequently
manage HRCSCC patients. Using these recommendations, a group of dermatologists and OCS were invited to
participate.
Invited participants were emailed a personalized
REDCap weblink to the survey and sent two reminders
over 4 weeks. Incomplete surveys were excluded. The
study was approved by the University of Texas at Austin
Dell Medical School institutional review board.

|

2.1

Statistical analysis

Descriptive summary statistics for survey responses were
reported as frequency (percentage). Consensus was determined a priori at 80% or more of respondents in agreement. Comparisons between dermatologists and OCS
were analyzed using Chi-square test (or Fisher's exact test
for a cell-count ≤5). SAS version 9.4 was used for statistical analysis (SAS Institute Inc.). A two-sided p-value ≤0.05
was considered statistically significant.

3
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RESULTS

A total of 337 physicians (n = 163, 48% dermatologists
and n = 174, 52% OCS) were invited to participate in
the study. One hundred and fifty-six (46%) physicians completed the survey, of which 89 (57%) were
dermatologists and 67 were (43%) OCS. Respondent
characteristics, including specialty, number of years
practicing, practice setting, and self-reported number
of HRCSCCs managed in the previous 12 months are
listed in Table 1.
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TABLE 1

Baseline demographics of survey respondents

Total respondents

Number of responses
(% of cohort)

Dermatologists

Other cancer
specialists (OCS)

156

89 (57.05%)

67 (42.95%)

Specialty
Med Dermatology/Dermatology Oncology

14 (8.97%)

Mohs

75 (48.08%)

Medical Oncology

15 (9.62%)

Surgical Oncology

1 (0.64%)

ENT/Head and Neck Surgery

27 (17.31%)

Plastic Surgery

3 (1.92%)

Radiation Oncology

21 (13.46%)

Region
USA

148 (94.87%)

83 (93.26%)

65 (97.01%)

UK

5 (3.21%)

5 (5.62%)

0

Canada

2 (1.28%)

1 (1.12%)

1 (1.49%)

Australia/New Zealand

1 (0.64%)

0

1 (1.49%)

Europe

0

0

0

Number of HRCSCC treated in the past 12 months
0

0

0

0

1–10

25 (16.03%)

12 (13.48%)

13 (19.40%)

11–25

75 (48.08%)

45 (50.56%)

30 (44.78%)

26–50

32 (20.51%)

14 (15.73%)

18 (26.87%)

>50

24 (15.38%)

18 (20.22%)

6 (9.95%)

Number of years in practice (post-residency)
0–5

46 (29.49%)

27 (30.34%)

19 (28.36%)

6–10

45 (28.85%)

27 (30.34%

18 (26.87%)

11–20

36 (23.08%)

19 (21.37%)

17 (25.37%)

>20

29 (18.59%)

16 (17.98%)

13 (19.40%)

Academics

136 (87.18%)

72 (80.90%)

64 (95.52%)

Private practice/closed multi-specialty

31 (19.87%)

22 (24.72%)

5 (7.46%)

VA

7 (4.49%)

6 (6.74%)

1 (1.49%)

Open multi-specialty group

1 (0.64%)

1 (1.12%)

0

Practice environment

Abbreviation: HRSCC, high-risk squamous cell carcinoma.
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High-risk features

Table S1 (ST1) lists the percentage of respondents selecting a feature as high risk.

3.1.1

|

Areas of consensus

Features selected by ≥80% of respondents included: depth
of invasion (DI) (n = 143, 92%), perineural invasion
(PNI) (n = 154, 99%), poor histologic differentiation (HD)
(n = 132, 85%), and immunosuppression (n = 141, 90%)
(Figure 1).

3.1.2

|

Areas of divergence

Clinical tumor diameter (CTD) and HD were significantly
more likely to be chosen by dermatologists as high risk
compared to OCS (79% vs. 54%; p = 0.001 and 99% vs. 66%;
p < 0.001, respectively) (Figure 1). Dermatologists considered >2 cm diameter, moderate differentiation, poor differentiation, spindle cell, desmoplasia, and infiltration to
be high risk significantly more often than OCS (p < 0.001,
p = 0.0005, <0.001, 0.001, 0.021, 0.011, respectively). OCS
were more likely to select any PNI as high risk (40% vs.
17%, p < 0.001), while dermatologists more often designated PNI of a large caliber nerve (≥0.1 mm diameter)
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Risk Category

Significant to Dermatologists

Significant to OCS

Clinical Tumor Diameter

Clinical Tumor Diameter >2cm

NSA

Tumor Depth*

NSA

NSA

PNI*

PNI >0.1mm

Any PNI

Histologic Differentiation*

Any Histologic Differenaon
Moderate differenaon
Poor differenaon
Spindle cell
Desmoplasia
Infiltrave

Immunosuppression*

NSA

|
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NSA

Stem Cell Transplant
Chronic Systemic Disease

Location

Non-hair bearing lip locaon
NSA
Scalp locaon
* Risk feature reached consensus among all respondents. Consensus was defined by >80% selecon.
Discordance was defined by chi square test with p value <0.05. NSA – No Significance Achieved
FIGURE 1

Consensus and discordance of risk features among respondents

as high risk (92% vs. 66%, p < 0.001). While a majority
of respondents considered patients with solid organ transplantation (SOTR) (n = 94; 60.3%) and hematologic malignancy (n = 113; 72.4%) at high risk for poor outcome,
OCS considered stem cell transplant (SCT), and chronic
systemic disease as high risk more often than dermatologists (p = 0.0285, 0.001, respectively).

3.2

|

Staging system utilization

Most dermatologists (89%) and OCS (93%) currently stage
CSCC tumors. OCS preferred to stage all tumors (n = 48,
72%), while dermatologists tended to stage only high-risk
tumors (n = 59, 66%, p-value <0.001). AJCC and BWH were
the predominate staging systems utilized. Dermatologists
(71%) were likely to utilize the Brigham and Women's
Hospital (BWH) staging system alone or in conjunction with American Joint Committee on Cancer (AJCC),
whereas OCS (71%) used only AJCC. Among those using
BWH staging, there was broad consensus that BWH T2b
and higher CSCC are high risk (100% of dermatologists,
100% of OCS). Among those using AJCC staging, there was
broad consensus that AJCC T3 and higher CSCC are high
risk (96% of dermatologists, 93% of OCS). (Table 2).

|

3.3

Disease management

A large number of respondents reported they do not use
staging systems to help consider whether to perform radiologic imaging, SLNB, post-operative radiation therapy
(PORT), adjuvant systemic therapy, or increased followup in HRCSCC (31%, 56%, 30%, 76%, 40%, respectively).
However, of those utilizing BWH staging, there was consensus that BWH T2b cases could be considered for radiologic imaging (98%, 100%), SLNB (95%, 100%), PORT (95%,
100%), and increased follow-up (98%, 100%) by dermatologists and OCS, respectively. For those utilizing AJCC
staging, there was consensus that AJCC T3 cases could be
considered for radiologic imaging (90%, 95%), SLNB (100%,
95%), PORT (94%, 93%), and increased follow-up (97%,
100%) by dermatologists and OCS, respectively. (Table 2).

4
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DISC USSION

Accurate identification of HRCSCC helps to ensure we develop robust staging systems, identify those at high risk of
poor outcomes, and provide precise treatments based on
risk. The purpose of this study was to provide a multidisciplinary perspective regarding HRCSCC risk assessment
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TABLE 2

Tumor staging utilization and management patterns

Do you currently stage CSCC tumors that present to your
practice?
Yes
No
No response
If you do stage tumors, which tumors do you stage?
All tumors
Suspected high risk
Other
If you do stage tumors, which staging system do you use?
AJCC
BWH
Both
Other
If you utilize staging criteria to identify HRCSCC, which
stages do you consider as high risk in AJCC?
T1 and higher
T2 and higher
T3 and higher
T4 and higher
If you utilize staging criteria to identify HRCSCC, which
stages do you consider as high risk in BWH-T?
T1 and higher
T2a and higher
T2b and higher
T3 and higher
If you use pre or post-operative radiologic imaging to
detect subclinical lymph node metastasis or distant
metastasis in a patient with HRCSCC, what staging do
you use to determine imaging?
AJCC
BWH
Both
Other
For which AJCC stage do you consider radiologic imaging
to detect subclinical lymph node metastasis or distant
metastasis?
T1 and higher
T2 and higher
T3 and higher
T4 and higher
For which BWH stage do you consider radiologic imaging
to detect subclinical lymph node metastasis or distant
metastasis?
T1 and higher
T2a and higher
T2b and higher
T3 and higher
If you use or recommend SLNB to search for sub-clinical
lymph node metastasis in a patient with HRCSCC,
what staging system do you use to determine SLNB?

Dermatologists

OCS

(n = 89)

(n = 67)

79 (89%)
8 (9%)
2 (2%)

62 (93%)
5 (8%)
0 (0%)

(n = 89)

(n = 67)

19 (24%)
59 (75%)
1 (1%)

48 (77%)
14 (23%)
0 (0%)

(n = 89)

(n = 67)

12 (13%)
26 (29%)
37 (42%)
14 (16%)

44 (71%)
1 (2%)
12 (19%)
10 (16%)

(n = 49)

(n = 56)

0 (0.0%)
25 (51%)
22 (45%)
1 (2%)

4 (7%)
20 (36%)
28 (50%)
2 (4%)

(n = 63)

(n = 13)

0 (0%)
7 (11%)
56 (89%)
0 (0%)

0 (0%)
1 (8%)
12 (92%)
0 (0%)

(n = 89)

(n = 67)

6 (6.7%)
34 (38.2%)
24 (27.0%)
25 (28.1%)

34 (50.7%)
4 (6.0%)
6 (9.0%)
23 (34.3%)

(n = 28)

(n = 40)

0 (0.0%)
11 (36.7%)
16 (53.3%)
1 (3.3%)

0 (0.0%)
16 (40.0%)
22 (55.0%)
0 (0.0%)

(n = 58)

(n = 10)

0 (0.0%)
3 (5.2%)
54 (93.1%)
1 (1.7%)

0 (0.0%)
2 (20.0%)
8 (80.0%)
0 (0.0%)

(n = 89)

(n = 67)

p-Value

<0.001

<0.001

<0.001*

N/A

N/A

<0.001

N/A

N/A

(Continues)

PATEL et al.

TABLE 2

  

|

99

(Continued)

AJCC
BWH
Both
Other
For which AJCC stage do you consider SLNB to detect
subclinical lymph node metastasis or distant
metastasis?
T1 and higher
T2 and higher
T3 and higher
T4 and higher
For which BWH stage do you consider SLNB to detect
subclinical lymph node metastasis or distant
metastasis?
T1 and higher
T2a and higher
T2b and higher
T3 and higher
If you use or recommend post-operative ART for a patient
with HRCSCC, what staging system do you use to
determine post-operative ART?
AJCC
BWH
Both
Other
For which AJCC stage do you consider post-operative ART
for a patient with HRCSCC?
T1 and higher
T2 and higher
T3 and higher
T4 and higher
For which BWH stage do you consider post-operative ART
for a patient with HRCSCC?
T1 and higher
T2a and higher
T2b and higher
T3 and higher
If you use or recommend post-operative adjuvant systemic
therapy for a patient with HRCSCC, what staging
system do you use to determine adjuvant therapy?
AJCC
BWH
Both
Other
For which AJCC stage do you consider post-operative
adjuvant systemic therapy for a patient with HRCSCC?
T1 and higher
T2 and higher
T3 and higher
T4 and higher

Dermatologists

OCS

p-Value

5 (5.6%)
23 (25.8%)
15 (16.9%)
46 (51.7%)

18 (26.9%)
5 (7.5%)
3 (4.5%)
41 (61.2%)

<0.001

(n = 20)

(n = 21)

0 (0%)
3 (15%)
17 (85%)
0 (0%)

0 (0%)
7 (33%)
13 (62%)
0 (0%)

(n = 38)

(n = 8)

0 (0%)
0 (0%)
36 (95%)
2 (5%)

0 (0.0%)
3 (38%)
5 (62%)
0 (0%)

(n = 89)

(n = 67)

6 (7%)
29 (33%)
27 (30%)
27 (30%)

36 (54%)
4 (6%)
7 (10%)
20 (30%)

(n = 33)

(n = 43)

0 (0%)
7 (21%)
24 (73%)
1 (3%)

0 (0%)
12 (8%)
28 (65%)
2 (5%)

(n = 66)

(n = 11)

0 (0%)
2 (4%)
51 (91%)
3 (5%)

0 (0%)
1 (9%)
10 (91%)
0 (0%)

(n = 89)

(n = 67)

2 (2%)
10 (11%)
7 (8%)
70 (79%)

15 (22%)
0 0%)
3 (4%)
49 (73%)

(n = 9)

(n = 18)

0 (0.0%)
1 (11%)
5 (56%)
2 (22%)

0 (0.0%)
3 (17%)
8 (44%)
5 (28%)

N/A

N/A

<0.001

N/A

N/A

<0.001

N/A

(Continues)
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TABLE 2

(Continued)

For which BWH stage do you consider post-operative
adjuvant systemic therapy for a patient with HRCSCC?
T1 and higher
T2a and higher
T2b and higher
T3 and higher
If you do recommend increased follow-up frequency
for a skin and lymph node evaluation for a patient
with HRCSCC, what staging system do you use to
recommend follow-up?
AJCC
BWH
Both
Other
For which AJCC stage do you consider increased follow-up
for a patient with HRCSCC?
T1 and higher
T2 and higher
T3 and higher
T4 and higher
For which BWH stage do you consider increased follow-up
for a patient with HRCSCC?
T1 and higher
T2a and higher
T2b and higher
T3 and higher

Dermatologists

OCS

(n = 17)

(n = 3)

0 (0%)
0 (0%)
10 (59%)
7 (41%)

0 (0%)
0 (0%)
2 (67%)
0 (0%)

(n = 89)

(n = 67)

6 (7%)
29 (33%)
26 (29%)
28 (31%)

25 (37%)
3 (5%)
5 (7%)
34 (51%)

(n = 32)

(n = 30)

0 (0%)
10 (31%)
21 (66%)
0 (0%)

2 (7%)
8 (27%)
20 (67%)
0 (0%)

(n = 55)

(n = 8)

0 (0%)
3 (5%)
51 (93%)
0 (0%)

0 (0%)
2 (25%)
6 (75%)
0 (0%)

p-Value

N/A

<0.001

N/A

N/A

*p-value reflects only comparison between those using exclusively AJCC or exclusively BWH-T.

and management. PNI, DI, HD, and immunosuppression
reached consensus as high-risk factors by all experts. PNI
≥0.1 mm diameter, CTD (including >2 cm tumor diameter), and HD (including moderate differentiation, poor
differentiation, spindle cell, desmoplasia, and infiltration)
were more likely to be chosen by dermatologists than OCS.
Our study demonstrates consensus in line with recent
reports validating high-risk features and poor outcomes
but also highlights the variability in definitions between
experts.9,10 The impact of such variability can be seen in
the two current leading clinical trials evaluating adjuvant
immunotherapy in HRCSCC; the inclusion criteria are
different for both trials and do not follow either AJCC or
BWH staging.12,13 Results of these trials will be variable,
making it difficult for clinicians or the NCCN to draw generalizable conclusions regarding adjuvant therapy.
Nearly all respondents selected PNI and 81% specified that nerve diameter >0.1 mm was a significant cut-
off. However, OCS were more likely to select any PNI
as a risk factor, while dermatologists were more likely
to specify PNI ≥0.1 mm diameter as high risk. This difference is critical as there is notable evidence in the
dermatology literature that PNI of nerves <0.1 mm in

diameter in the absence of other risk factors does not
impact prognosis.14,15 The lack of widespread discussion
in the oncology literature may explain this variability.
Dermatologists and Mohs surgeons also dedicate a large
portion of their practice to HRCSCC, while most OCS
are unlikely to have HRCSCC focus alone. While current
staging and practice guidelines include PNI as a risk factor; ambiguity remains regarding management of the
range of PNI and the variability of understanding true
risk may lead to overtreatment in patients with small-
caliber PNI.10,16
Immunosuppression is another feature with variable response. While clinical factors are typically not
included in staging systems, there was a clear consensus of immunosuppression, and specifically SOTRs, as
an important risk factor. This is unsurprising given that
it is well known that SOTR who develop CSCC have
worse outcomes than immunocompetent patients.17,18
However, the identified risk from other immunosuppressive conditions was more variable between experts
with OCS more likely to consider stem cell transplant
and chronic systemic diseases as high risk compared to
dermatologists. This is notable considering that evidence

Tumor with gross cortical bone/marrow invasion

T4

1 High-risk factor
2–3 High-risk factors
≥4 High-risk factors

T2a

T2b

T3

Trunk, extremities <2 cm

Well-defined

Primary

(−)

(−)

(−)

(−)

Well or moderately differentiated

(−)

≤6 mm and no invasion beyond subcutaneous fat

(−)

(−)

Borders

Primary vs. recurrent

Immunosuppression

Site of prior radiation therapy or
chronic inflammatory process

Rapidly growing tumor

Neurologic symptoms

Degree of differentiation

Acantholytic, adenosquamous,
desmoplastic, or metaplastic
subtypes

Depth, thickness, or level of
invasion

Perin-eural involvement

Lymphatic or vascular
involvement

Low Risk

Location/size

NCCN Version 1.2021

(+)

Tumor cells within the nerve sheath
of a nerve lying deeper than the
dermis or measuring >0.1 mm

>6 mm or invasion beyond
subcutaneous fat

(+)

Poorly differentiated

(+)

(+)

(+)

(+)

Recurrent

Poorly defined

>4 cm any location

Very High Risk

  

(−)

(+)

>6 mm or invasion beyond subcutaneous fat

(+)

Poorly differentiated

(+)

(+)

(+)

(+)

Recurrent

Poorly defined

Trunk, extremities ≥2 cm
Head, neck, hands, feet, pretibial, and anogenital
(any size)

High Risk

*High-risk factors: Tumor diameter 2 cm, invasion beyond subcutaneous fat, poorly differentiated, and perineural invasion

No high-risk factors

T1

T stage

Risk factors

Tumor diameter ≥4 cm, or minor bone erosion, or perineural invasion, or deep invasion

T3

BWH

Tumor diameter ≥2 cm and <4 cm in greatest dimension

T2

Risk Factors (Head and Neck Only)
Tumor diameter <2 cm

CSCC staging and management systems

T1

T stage

AJCC

TABLE 3
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of increased risk is minimal in these conditions.19 The
presence of immunosuppression needs clarity in regard
to how to best incorporate this information with staging
systems to make management decisions.
Uncertainty remains regarding what staging systems
are best for risk assessment and management decisions
for CSCC. Dermatologists utilize BWH staging more frequently than OCS, either on its own or in conjunction
with AJCC, while OCS generally preferred AJCC. This
is likely due to BWH being developed by dermatologists
and is well discussed at dermatology conferences and in
the dermatology literature.6,7 OCS are likely accustomed
to AJCC staging for other cancers and may thus prefer
it. BWH has been shown to be superior to AJCC and
many of the BWH risk factors were incorporated into the
update from the seventh to eighth edition of AJCC, but
with only 40% of respondents utilizing AJCC, it clearly
needs further refinement before it is utilized widely.11,20
Furthermore, 15% of respondents noted utilizing neither
system highlighting a clear practice gap in the staging of
CSCC.
There was consensus among those who used AJCC and
BWH that tumor stage ≥AJCC T3 or ≥BWH T2b should
be considered high-risk and radiologic imaging, SLNB, adjuvant radiation therapy, and increased follow-up would
be considered in these tumors. This threshold to consider
adjuvant therapy is not surprising given the number of
studies that have shown high poor outcomes rates in these
tumors.21,22 However, the exact clinical scenarios and
management options that should be employed in these
patients are uncertain. Specifically, not all BWH T2b and
AJCCT3 cases portend sufficient risk to warrant adjuvant
therapy blindly, and data and guidelines vary regarding
recurrence risk and management of this CSCC subset.
Furthermore, there are a number of AJCC T2 and BWH
T2a tumors that metastasize and lead to death.19 This may
explain why 43% of AJCC users denote T2 to be high risk
and that AJCC T2/T3 tumors have a difficult overlap to
discern between. The NCCN also recently created a new
“very high risk” designation to unify management of a
subset of tumors that have poor outcomes. (Table 3).
More concerning is that a large number of respondents
are not using either system to drive their decision to perform radiologic imaging, SLNB, adjuvant radiation therapy, adjuvant systemic therapy, or increased follow-up.
There is no clear consensus about how to utilize T staging to drive management despite evidence of the benefit
of additional interventions in HRCSCC.23,24 Uncertainty
is expected given the inconsistent risk estimates by T
stage.19,20 Furthermore, the scarcity of staging system
implementation in clinical practice may be compounded
by the high incidence of CSCC, together with the T stage

heterogeneity, as well as the potential lack of concern or
knowledge about this tumor compared with melanoma.
The underutilization of consistent and concrete guidelines signifies a major shortcoming in the care of patients
with CSCC, especially HRCSCC, and needs urgent rectifying with accurate T-stage risk estimates and evidence-
based treatment modalities by disease stage.
A strength of this study is that we surveyed experts in
cutaneous oncology who treat a high number of HRCSCC,
which allowed answers to be based on collective experiences. A limitation is that the panelists were identified
from mainly academic tertiary referral centers and thus
results may not be generalizable to all physician practice
patterns. The survey was developed based on accepted literature evidence and current staging, but given the lack of
complete understanding of CSCC, some answer choices
in the survey may have been omitted. In these cases, many
experts entered text that was not categorizable and thus
not analyzed.
The results of this survey illustrate areas of consensus
and equipoise between multispecialty experts that manage high risk and advanced CSCC. While there are many
areas of agreement, there is significant room for communication and education. But most importantly, these results highlight the need for multidisciplinary consensus
building and clinical trials to establish evidence-based criteria for risk stratification and management of HRCSCC.
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